The stock of Retrophin Inc (NASDAQ:RTRX) is a huge mover today! The stock decreased 5.27% or $0.98 during the last trading session, hitting $17.62. About 919,850 shares traded hands or 146.88% up from the average. Retrophin Inc (NASDAQ:RTRX) has risen 28.81% since April 4, 2016 and is uptrending. It has outperformed by 27.72% the S&P500.
The move comes after 9 months negative chart setup for the $647.20 million company. It was reported on Nov, 4 by Barchart.com. We have $16.74 PT which if reached, will make NASDAQ:RTRX worth $32.36 million less.
Retrophin Inc (NASDAQ:RTRX) Ratings Coverage
Out of 3 analysts covering Retrophin (NASDAQ:RTRX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Retrophin has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. BMO Capital Markets initiated Retrophin Inc (NASDAQ:RTRX) rating on Tuesday, April 12. BMO Capital Markets has “Outperform” rating and $25 price target. JMP Securities initiated Retrophin Inc (NASDAQ:RTRX) on Monday, November 2 with “Mkt Outperform” rating. Zacks downgraded the shares of RTRX in a report on Wednesday, August 12 to “Buy” rating.
According to Zacks Investment Research, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include ChenodalÂ®, Cholbam, and ThiolaÂ®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego.”
Insitutional Activity: The institutional sentiment increased to 1.3 in Q2 2016. Its up 0.23, from 1.07 in 2016Q1. The ratio improved, as 15 funds sold all Retrophin Inc shares owned while 29 reduced positions. 12 funds bought stakes while 45 increased positions. They now own 38.66 million shares or 4.59% more from 36.97 million shares in 2016Q1.
Employees Retirement Association Of Colorado holds 0% of its portfolio in Retrophin Inc (NASDAQ:RTRX) for 10,796 shares. Pnc Financial Serv Grp, a Pennsylvania-based fund reported 163 shares. Invesco Limited accumulated 1.17M shares or 0.01% of the stock. Connor Clark And Lunn Ltd holds 0% or 20,950 shares in its portfolio. Blackrock Investment Limited Liability Company has 0% invested in the company for 147,822 shares. Legal And General Plc last reported 0% of its portfolio in the stock. Metropolitan Life Insurance Com Ny has 24,629 shares for 0% of their US portfolio. Cornerstone Mgmt Llc accumulated 0% or 7,900 shares. Tekla Capital Management Limited Liability Co last reported 0.24% of its portfolio in the stock. Millennium, a New York-based fund reported 776,294 shares. Park West Asset holds 1.44% or 800,000 shares in its portfolio. The Switzerland-based Credit Suisse Ag has invested 0% in Retrophin Inc (NASDAQ:RTRX). Franklin Resources Incorporated has invested 0.01% of its portfolio in Retrophin Inc (NASDAQ:RTRX). Citadel Advisors has 582,825 shares for 0.01% of their US portfolio. Everpoint Asset Ltd Liability Corporation has 0.19% invested in the company for 550,000 shares.
Insider Transactions: Since June 1, 2016, the stock had 0 insider buys, and 2 selling transactions for $297,343 net activity. The insider Shih Alvin sold $142,059.
More recent Retrophin Inc (NASDAQ:RTRX) news were published by: Fool.com which released: “Why Shares of Retrophin Inc Are Soaring Today” on September 07, 2016. Also Fool.com published the news titled: “Why Retrophin Inc was Down Today” on February 10, 2016. Reuters.com‘s news article titled: “Retrophin to pay $3 million in US lawsuit over Shkreli’s tenure” with publication date: February 03, 2016 was also an interesting one.
RTRX Company Profile
Retrophin, Inc. (Retrophin), incorporated on February 7, 2008, is a biopharmaceutical company. The Firm is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Firm sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). The Company’s Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. The Company’s Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. The Company’s Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.